31 results
6-K
EX-99.1
EVAX
Evaxion Biotech A/S
5 Feb 24
Securities Purchase Agreement
7:00am
to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case … as could not have or reasonably be expected to result in a Material Adverse Effect.
(m) Environmental Laws. The Company and its Subsidiaries (i
F-1/A
EVAX
Evaxion Biotech A/S
30 Jan 24
Registration statement (foreign) (amended)
3:16pm
as assessed by the facility and utility environmental monitoring program;
ineffective process, equipment or analytical change management, resulting … to comply with environmental, health and safety and regulations, we could become subject to fines or penalties or incur costs that could materially harm our
F-1/A
EX-10.1
EVAX
Evaxion Biotech A/S
30 Jan 24
Registration statement (foreign) (amended)
3:16pm
limitation all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality … ) Environmental Laws. The Company and its Subsidiaries (i) are in compliance with all applicable federal, state, local and foreign laws relating
F-1
EVAX
Evaxion Biotech A/S
12 Jan 24
Registration statement (foreign)
5:17pm
procedures;
facility contamination as assessed by the facility and utility environmental monitoring program;
ineffective process, equipment … to comply with environmental, health and safety and regulations, we could become subject to fines or penalties or incur costs that could materially harm
6-K
EX-10.1
hve1z9keayqm
21 Dec 23
Current report (foreign)
4:45pm
6-K
EX-10.2
nqg vnius0ij0zt
21 Dec 23
Current report (foreign)
4:45pm
6-K
EX-1.1
rnswjiykzvrz
4 Oct 22
Current report (foreign)
8:56am
6-K
EX-10.1
yeilr7
7 Jun 22
Evaxion Biotech Secures Equity Financing of up to $40 Million from Lincoln Park Capital
5:05pm
424B4
sxf8yptb18t8ff4
5 Nov 21
Prospectus supplement with pricing info
4:47pm
6-K
EX-1.1
oblmum keg1
5 Nov 21
Evaxion Biotech Announces Pricing of $24.0 Million Follow-on Public Offering
8:30am
F-1/A
idsu4gq62jz8dg2 a85
3 Nov 21
Registration statement (foreign) (amended)
7:50am
F-1
EX-1.1
gh3gqph
26 Oct 21
Registration statement (foreign)
7:02am
F-1
ajxy1zc5cvd oxr5b
26 Oct 21
Registration statement (foreign)
7:02am
6-K
EX-99.2
7eb2neraby 37q
25 Oct 21
Evaxion Biotech Announces Clinical Collaboration to Evaluate Lead Product Candidate with KEYTRUDA® (pembrolizumab) in Patients with Melanoma
6:00am
DRS
fz8rqg9f
25 Jun 21
Draft registration statement
12:00am
20-F
lco8jyq1qf1jua
7 Apr 21
Annual report (foreign)
4:31pm
424B4
ihaf0zt18r9dpf1pj
5 Feb 21
Prospectus supplement with pricing info
4:53pm